Embla Medical hf.
OSSFF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $236 | $236 | $203 | $225 |
| % Growth | -0% | 16.4% | -9.8% | – |
| Cost of Goods Sold | $99 | $99 | $84 | $92 |
| Gross Profit | $137 | $137 | $119 | $133 |
| % Margin | 58.2% | 58.1% | 58.7% | 59.2% |
| R&D Expenses | $10 | $10 | $9 | $10 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $91 | $93 | $88 | $91 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | $0 | $0 | $0 |
| Operating Expenses | $100 | $103 | $97 | $101 |
| Operating Income | $37 | $34 | $22 | $32 |
| % Margin | 15.7% | 14.3% | 10.8% | 14.2% |
| Other Income/Exp. Net | -$3 | -$6 | -$6 | -$7 |
| Pre-Tax Income | $34 | $28 | $16 | $25 |
| Tax Expense | $8 | $7 | $4 | $6 |
| Net Income | $26 | $21 | $12 | $18 |
| % Margin | 10.9% | 9% | 6% | 8.1% |
| EPS | 0.061 | 0.05 | 0.028 | 0.044 |
| % Growth | 21.2% | 78.6% | -36.4% | – |
| EPS Diluted | 0.061 | 0.05 | 0.028 | 0.044 |
| Weighted Avg Shares Out | 425 | 418 | 434 | 414 |
| Weighted Avg Shares Out Dil | 425 | 418 | 434 | 414 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $1 | $1 |
| Interest Expense | $6 | $5 | $5 | $6 |
| Depreciation & Amortization | $16 | $15 | $14 | $15 |
| EBITDA | $55 | $45 | $35 | $44 |
| % Margin | 23.2% | 18.9% | 17% | 19.7% |